Amgen - AMGN Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 4 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.

14 Wall Street analysts have issued 1 year price targets for Amgen's stock. Their AMGN share price forecasts range from $182.00 to $300.00. On average, they anticipate the company's share price to reach $248.19 in the next twelve months. This suggests that the stock has a possible downside of 13.1%.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

Amgen's stock was trading at $224.97 at the start of the year. Since then, AMGN shares have increased by 26.9% and is now trading at $285.51.
View the best growth stocks for 2022 here.

Amgen saw a decline in short interest in November. As of November 15th, there was short interest totaling 10,430,000 shares, a decline of 11.4% from the October 31st total of 11,770,000 shares. Based on an average daily trading volume, of 2,800,000 shares, the short-interest ratio is presently 3.7 days. Approximately 2.0% of the company's shares are sold short.
View Amgen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our AMGN earnings forecast.

Amgen Inc. (NASDAQ:AMGN) released its earnings results on Thursday, November, 3rd. The medical research company reported $4.70 EPS for the quarter, topping analysts' consensus estimates of $4.43 by $0.27. The medical research company earned $6.65 billion during the quarter, compared to analysts' expectations of $6.56 billion. Amgen had a trailing twelve-month return on equity of 287.23% and a net margin of 25.96%. The company's revenue was down .8% compared to the same quarter last year. During the same period last year, the business earned $4.67 earnings per share.
Read the conference call transcript.

Amgen declared a quarterly dividend on Friday, October 28th. Stockholders of record on Thursday, November 17th will be paid a dividend of $1.94 per share on Thursday, December 8th. This represents a $7.76 annualized dividend and a yield of 2.72%. The ex-dividend date of this dividend is Wednesday, November 16th.
Read our dividend analysis for AMGN.

Amgen (NASDAQ:AMGN) pays an annual dividend of $7.76 per share and currently has a dividend yield of 2.71%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 62.23%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 41.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

Amgen updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of $17.25-$17.85 for the period, compared to the consensus EPS estimate of $17.50. The company issued revenue guidance of $26.00 billion-$26.30 billion, compared to the consensus revenue estimate of $26.14 billion.

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.89%), BlackRock Inc. (8.78%), State Street Corp (5.45%), Primecap Management Co. CA (2.92%), Royal Bank of Canada (1.14%) and Bank of New York Mellon Corp (1.12%). Insiders that own company stock include David Piacquad, Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMGN stock can currently be purchased for approximately $285.51.

Amgen (NASDAQ:AMGN) has a market capitalization of $152.34 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $12.47 on an earnings per share basis.

The company employs 24,200 workers across the globe.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.